Adam de Havenon1, Chelsea Meyer2, J Scott McNally3, Matthew Alexander3, Lee Chung2. 1. Department of Neurology, University of Utah, Salt Lake City, UT, USA. adam.dehavenon@hsc.utah.edu. 2. Department of Neurology, University of Utah, Salt Lake City, UT, USA. 3. Department of Radiology, University of Utah, Salt Lake City, UT, USA.
Abstract
PURPOSE OF REVIEW: Subclinical cerebrovascular disease (sCVD) is highly prevalent in older adults. The main neuroimaging findings of sCVD include white matter hyperintensities and silent brain infarcts on T2-weighted MRI and cerebral microbleeds on gradient echo or susceptibility-weighted MRI. In this paper, we will review the epidemiology of sCVD, the current evidence for best medical management, and future directions for sCVD research. RECENT FINDINGS: Numerous epidemiologic studies show that sCVD, in particular WMH, is an important risk factor for the development of dementia, stroke, worse outcomes after stroke, gait instability, late-life depression, and death. Effective treatment of sCVD could have major consequences for the brain health of a substantial portion of older Americans. Despite the link between sCVD and many vascular risk factors, such as hypertension or hyperlipidemia, the optimal medical treatment of sCVD remains uncertain. Given the clinical equipoise about the risk versus benefit of aggressive medical management for sCVD, clinical trials to examine pragmatic, evidence-based approaches to management of sCVD are needed. Such a trial could provide much needed guidance on how to manage a common clinical scenario facing internists and neurologists in practice.
PURPOSE OF REVIEW: Subclinical cerebrovascular disease (sCVD) is highly prevalent in older adults. The main neuroimaging findings of sCVD include white matter hyperintensities and silent brain infarcts on T2-weighted MRI and cerebral microbleeds on gradient echo or susceptibility-weighted MRI. In this paper, we will review the epidemiology of sCVD, the current evidence for best medical management, and future directions for sCVD research. RECENT FINDINGS: Numerous epidemiologic studies show that sCVD, in particular WMH, is an important risk factor for the development of dementia, stroke, worse outcomes after stroke, gait instability, late-life depression, and death. Effective treatment of sCVD could have major consequences for the brain health of a substantial portion of older Americans. Despite the link between sCVD and many vascular risk factors, such as hypertension or hyperlipidemia, the optimal medical treatment of sCVD remains uncertain. Given the clinical equipoise about the risk versus benefit of aggressive medical management for sCVD, clinical trials to examine pragmatic, evidence-based approaches to management of sCVD are needed. Such a trial could provide much needed guidance on how to manage a common clinical scenario facing internists and neurologists in practice.
Authors: Franz Fazekas; F Barkhof; L O Wahlund; L Pantoni; T Erkinjuntti; P Scheltens; R Schmidt Journal: Cerebrovasc Dis Date: 2002 Impact factor: 2.762
Authors: F-E de Leeuw; J C de Groot; M Oudkerk; J C M Witteman; A Hofman; J van Gijn; M M B Breteler Journal: Brain Date: 2002-04 Impact factor: 13.501
Authors: F E de Leeuw; J C de Groot; E Achten; M Oudkerk; L M Ramos; R Heijboer; A Hofman; J Jolles; J van Gijn; M M Breteler Journal: J Neurol Neurosurg Psychiatry Date: 2001-01 Impact factor: 10.154
Authors: R N Bryan; J Cai; G Burke; R G Hutchinson; D Liao; J F Toole; A P Dagher; L Cooper Journal: AJNR Am J Neuroradiol Date: 1999-08 Impact factor: 3.825
Authors: Alan J Thomas; John T O'Brien; Sue Davis; Clive Ballard; Robert Barber; Rajesh N Kalaria; Robert H Perry Journal: Arch Gen Psychiatry Date: 2002-09
Authors: Marlene Lorgen-Ritchie; Alison D Murray; Roger Staff; Anne C Ferguson-Smith; Marcus Richards; Graham W Horgan; Louise H Phillips; Gwen Hoad; Chris McNeil; Antonio Ribeiro; Paul Haggarty Journal: Sci Rep Date: 2021-01-13 Impact factor: 4.379
Authors: Maria Luz Alonso-Alonso; Ana Sampedro-Viana; Sabela Fernández-Rodicio; Marcos Bazarra-Barreiros; Alberto Ouro; Tomás Sobrino; Francisco Campos; José Castillo; Pablo Hervella; Ramón Iglesias-Rey Journal: Int J Mol Sci Date: 2022-08-22 Impact factor: 6.208